[San Francisco Business Times] As several companies emerge with the label of AI drug discovery, this San Francisco company has hundreds of projects and now a big funding round.
[TechCrunch] With a slew of partnerships with large pharmaceutical companies under its belt and the successful spin out of at least one new company, Atomwise has already proved the value of its machine learning platform for discovering and commercializing potential small molecule therapies for a host of conditions.
[Wall Street Journal] Atomwise Inc., which uses artificial intelligence to help academic and commercial scientists discover new medicines, has raised $123 million to expand and build its own pipeline of experimental drugs.
Strategic collaboration to integrate AI technology, drug development expertise and ecosystem of partners for the commercialization of promising early-stage research CLEVELAND & SAN FRANCISCO–(BUSINESS WIRE)–BioMotiv, a mission-driven biopharma company, and Atomwise, the leader in using artificial intelligence (AI) for small molecule discovery, today announced a strategic collaboration to co-develop therapies. The organizations will form co-owned, joint […]
Companies to continue crop protection development programs January 07, 2020 08:30 AM Eastern Standard Time MONHEIM, Germany & SAN FRANCISCO–(BUSINESS WIRE)–Bayer and Atomwise, the leader in artificial intelligence (AI) for drug discovery, today announced the companies will continue the development of two crop protection programs. Farmers across the world are facing an increase in weed, insect and […]